Training program to improve memory in patients with acquired brain injury

Evaluation of the Karman Line Memory Strategy Training, a Combined Computerized and Face-to-face Compensatory Treatment Targeting Memory Complaints After Acquired Brain Injury, Using Single-case Experimental Design Methodology

Not applicable Interventional Klimmendaal Revalidatiespecialisten · NCT06774287

This study is testing a new memory training program to see if it can help people with mild to moderate memory problems caused by brain injuries.

Quick facts

PhaseNot applicable
Study typeInterventional
Enrollment6 (estimated)
Ages18 Years to 75 Years
SexAll
SponsorKlimmendaal Revalidatiespecialisten Research network
Locations1 site (Arnhem, Gelderland)
Trial IDNCT06774287 on ClinicalTrials.gov

What this trial studies

This study evaluates the Karman Line Memory Strategy Training, a combined computerized and face-to-face approach designed to enhance memory performance in patients with acquired brain injury (ABI). The program targets individuals with mild to moderate memory deficits, utilizing effective compensation strategies to optimize their cognitive functioning. Participants will undergo assessments to confirm their eligibility based on memory complaints and neuropsychological evaluations. The intervention aims to provide a more efficient treatment option compared to existing labor-intensive memory training programs.

Who should consider this trial

Good fit: Ideal candidates are adults aged 18-75 with mild to moderate memory deficits due to non-progressive acquired brain injury.

Not a fit: Patients with severe memory deficits or those unable to communicate in Dutch may not benefit from this study.

Why it matters

Potential benefit: If successful, this program could significantly improve the memory function and daily life activities of patients with acquired brain injury.

How similar studies have performed: While there are existing memory training programs, this approach is novel in its combination of computerized and face-to-face strategies specifically tailored for ABI patients.

Eligibility criteria

Show full inclusion / exclusion criteria
Inclusion criteria:

* presence of subjective memory complaints. Memory complaints will be operationalized as ≥1 standard deviation on the total score of the EMQ-R questionnaire in comparison with the healthy control norm.
* presence of mild to moderate objective memory deficits, objectified with neuropsychological assessment for clinical purposes. Mild to moderate memory deficits will be operationalized as test score ≥1 standard deviation (SD) and \<2 SD in comparison to the normative mean on at least two separate memory measures and no more than one measure ≥ 2SD. For each task the norm data that is described in the test manual will be used.
* Age: 18-75 years
* Non-progressive acquired brain injury
* Minimal time post-onset of 3 months
* Outpatient rehabilitation
* Living independently at home
* Premorbid functioning: score 4 on the Verhage scale

Exclusion criteria:

* Severe memory deficits
* Inability to speak and/or understand the Dutch language
* Severe disorders in executive functioning
* Severe psychiatric problems
* Neurodegenerative disorders
* Substance abuse
* Aphasia
* Neglect
* No access to a smartphone and a tablet/laptop with internet connection
* Unable to look at a computer screen for 15 minutes
* Unable to operate a keyboard or computer mouse.
* No informed consent

Where this trial is running

Arnhem, Gelderland

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions Acquired Brain InjuryCompensatory brain gamesmemory disorder
Last reviewed 2026-06-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.